Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Other Non-Current Liabilities (2020 - 2025)

Arcutis Biotherapeutics has reported Other Non-Current Liabilities over the past 6 years, most recently at $431000.0 for Q4 2025.

  • Quarterly results put Other Non-Current Liabilities at $431000.0 for Q4 2025, down 24.39% from a year ago — trailing twelve months through Dec 2025 was $431000.0 (down 24.39% YoY), and the annual figure for FY2025 was $431000.0, down 24.39%.
  • Other Non-Current Liabilities for Q4 2025 was $431000.0 at Arcutis Biotherapeutics, up from $360000.0 in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for ARQT hit a ceiling of $849000.0 in Q4 2023 and a floor of $12000.0 in Q2 2022.
  • Median Other Non-Current Liabilities over the past 5 years was $306000.0 (2024), compared with a mean of $268000.0.
  • Biggest five-year swings in Other Non-Current Liabilities: plummeted 83.97% in 2021 and later surged 85.57% in 2025.
  • Arcutis Biotherapeutics' Other Non-Current Liabilities stood at $25000.0 in 2021, then tumbled by 52.0% to $12000.0 in 2022, then surged by 6975.0% to $849000.0 in 2023, then crashed by 32.86% to $570000.0 in 2024, then dropped by 24.39% to $431000.0 in 2025.
  • The last three reported values for Other Non-Current Liabilities were $431000.0 (Q4 2025), $360000.0 (Q3 2025), and $360000.0 (Q2 2025) per Business Quant data.